LGLaura S. Graham

Laura S. Graham

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura S. Graham has a total of 208 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ADC Target Signatures in Urothelial Carcinoma: A Transcriptomic Framework for Precision Therapy

    by Edwin Lin, Feng Bing-Jian, Zeynep Irem Ozay, Georges Gebrael, Varun Nandakumar, Ethan Murdock, Haoran Li, Daniel Grass, Eric Singer, Laura Graham, et al.

    From the 6th Binaytara Precision Oncology Summit: At The Forefront of Targeted Cancer Therapy

  • Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer

    by Christopher Choi, Matthew Labriola, Nicholas Henderson, Alec Chu, Clara Hwang, Pedro C. Barata, Frank Cameron Cackowski, Amanda Broderick, Rana R. McKay, Mehmet Asim Bilen, et al.

    Purpose Smoking has been associated with increased metastatic prostate cancer mortality, but the mechanisms behind this are largely unknown. We hypothesized that smoking increases the risk of genetic alterations associated with aggressive disease and/or the transformation to neuroendocrine prostate cancer (NEPC). Patients and methods We utilized the Prostate Cancer Precision Medicine Multi-institutional Collaborative Effort (PROMISE) clinical genomic database for this retrospective analysis. We associated patient characteristics and tumor genetic data with smoking exposure at diagnosis (current, former, never and pack years) and with clinical outcomes, including overall survival (OS) from diagnosis or time to developing metastatic disease and NEPC status. Results We identified 2353 men with prostate cancer and next generation somatic tumor sequencing evaluable for analysis in PROMISE, including 8% current, 39% former, and 52% never smokers. Current smokers were more likely to be younger and to have metastatic (M1 or N1) disease at diagnosis, and less likely to have prior local therapy (all p < 0.001). Current smoking was associated with worse OS from diagnosis (99.9 mo vs 137.6 mo, HR 1.42, 95% CI 1.14–1.77), which remained significant after adjusting for disease characteristics. We found no difference in the percentage of NEPC at initial diagnosis or at any time between current, former, and never smokers (p = 0.8). We found positive associations between smoking status and genetic alterations in SPOP (current: 15%, former 6.7%, never 3.8%; p = 0.018), FGFR1 (current 10%, former 0.4%, never 1.1% p = 0.001), and ARID1A (current 5.1%, former 2.2%, never 0.4%; p = 0.035) in patients with metastatic androgen pathway modulator sensitive prostate cancer (APMS). Conclusion Active smoking is associated with worse overall and prostate cancer specific survival as compared to never/former smoking and was associated with specific tumor genetic alterations but not small cell/NEPC transformation.

  • Genetic variation and response to platinum chemotherapy in cancer treatment: a review article

    by Ryan S. Hilton, Laura S. Graham

    1. Cisplatin {cis- [PtCl2(NH3)2]}, ushered in the era of platinum-based chemotherapy after its potent anti-neoplastic properties were identified in the 1960s [1]. Its clinical success catalyzed the...

  • Improving Genetic Testing Uptake in Prostate Cancer: Outcomes From a Multidisciplinary Clinic Evaluation

    by Laura S. Graham, Aditya Mantha, Chiagozie Paul-Onyia, Lisa Ku, Breana Mitchell, Marie E. Wood

    PURPOSE: The National Comprehensive Cancer Network recommends germline genetic testing for patients with prostate cancer and high-risk features or a suggestive family history. In 2024, the University of Colorado Urological Oncology Multidisciplinary Clinic (MDC) transitioned from a referral-based to a mainstream genetic testing model to streamline access and improve completion rates. We report the impact of this implementation on genetic testing uptake and subsequent genetic counseling recommendations. METHODS: The impact of a quality improvement initiative implemented in 2024 was assessed by comparing patients with prostate cancer evaluated at the urologic oncology MDC in consecutive years. In 2024, patients seen in MDC who met criteria for genetic testing were offered testing with a mainstream genetic testing model. These patients were then compared with eligible patients who were seen in 2023 when a traditional referral-based testing model was used. RESULTS: A total of 432 patients were evaluated (190 in 2023, 242 in 2024). Of those, 112 patients in 2023 and 115 patients in 2024 met eligibility criteria. Completion of genetic testing increased significantly from 30% (34/112) in 2023 to 72% (83/115) in 2024 ( P < .001). Among patients tested with the mainstream model in 2024, pathogenic variants were identified in 10 (12%) individuals. Seven of 10 patients with pathogenic variants completed post-test genetic counseling, where cascade testing and preventive screening recommendations were discussed. CONCLUSION: Transitioning to a provider-initiated, mainstream genetic testing model significantly improved pretest genetic testing completion rates within a multidisciplinary prostate cancer clinic. This integrated approach enhanced care coordination and expedited genetic evaluation, potentially representing a scalable framework to expand precision oncology and hereditary cancer risk assessment in prostate cancer management.


  • Open Access

    Insulin Pathway Changes in Localized Prostate Cancer: A Multi-Institutional Analysis

    by Evan R. Adler, Anwaruddin Mohammad, Pankaj Kumar, Robert J. Rounbehler, Michelle L. Churchman, Laura S. Graham, Eric A. Singer, Bodour Salhia, Adanma Ayanambakkam, Kenneth G. Nepple, et al.

    Background: Prostate cancer is a heterogeneous disease with variable clinical outcomes. If localized, the patient may be cured. However, prostate cancer is lethal if recurrence/progression to metastatic castrate resistant disease occurs. Thus, there is an unmet need to further understand the molecular underpinnings of this progression. Epidemiologic studies show that increased risk of developing and dying from prostate cancer has been associated with elevated serum IGF-1 levels, hyperinsulinemia and metabolic syndrome. Alterations in insulin pathway genes, such as PTEN, FOXO, and PIK3CA, are mutated in up to 32%, 15%, and 11% of localized prostate tumors, respectively. We aimed to further characterize expression of insulin pathway genes in localized prostate cancers in an effort to (1) provide insights into potential mechanisms of progression to metastatic disease and (2) try to further enrich for those prostate tumors that portend worse survival outcomes. Methods: Using the multi-institutional Oncology Research Information Exchange Network (ORIEN) database, gene expression data was analyzed from localized prostate cancer tumors. The raw counts were first normalized, and 176 genes related to the insulin receptor and its downstream pathways were then subset and used for clustering using the non-negative matrix factorization (NMF). The NMF cluster analysis was performed in an attempt to separate gene expression into two groups. Gene Set Enrichment Analysis (GSEA) was then performed between the two groups that had been separated by cluster analysis to determine homology between other GSEA sets. Kaplan–Meier curves were used to assess median overall survival. Cox analysis was performed to generate the adjusted KM curve. Mediation analysis was conducted to determine the relationship between cluster status, TN stage, and survival. Results: Cluster analysis revealed two distinct groups of insulin gene expression, cluster 1 (n = 96) and cluster 2 (n = 337). Compared with cluster 2, cluster 1 consisted of decreased expression of PTEN (p < 0.001) and PIK3R1 (p < 0.001), along with increases in the expression of AKT1 (p < 0.001), IRS1/2 (p < 0.001), FASN (p < 0.001), IGFBP2 (p < 0.001), and MTOR (p < 0.001). GSEA analysis revealed changes in lipid metabolism and WNT secretion pathways in cluster 1. Cluster 2 GSEA showed pathway changes related to DNA damage repair and testosterone. Patient characteristics between clusters differed significantly in the T and N stages of tumor but not in other ways. In unadjusted analysis, median overall survival was estimated at 117 months and 232 months for cluster 1 and cluster 2, respectively (p < 0.05). The proportion of patients who went on to develop metastases (p < 0.05) or need chemotherapy (p < 0.05) was increased in cluster 1 compared to cluster 2. Repeat survival analysis adjusted for confounders (T stage, N stage, age at diagnosis, pathologic grade) showed no difference in survival between clusters. Mediation analysis showed that the contribution of cluster status to survival was independent of T or N stage. Conclusions: A subset of localized prostate cancer patients demonstrated linked insulin pathway changes that are consistent with prior studies describing a pattern of insulin dysregulation. Though the group characterized by insulin dysregulation initially showed worse survival outcomes, this difference disappeared when controlling for confounders. Though baseline differences in tumor stage seemed to most readily explain the difference in survival between clusters, mediation analysis showed that the effect of cluster status on survival was independent of tumor stage. This suggests that other confounders, such as pathologic grade or baseline age, may explain the survival difference.

  • Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer

    by Deepak Kilari, Nicholas C. Henderson, Kyra Yamamoto, Ye Yao, Clara Hwang, Pedro C. Barata, Mehmet Asim Bilen, Laura Graham, Rohan Garje, Shoshana Rothstein, et al.

    PURPOSE: Previous studies suggest that SPOP mutations result in increased sensitivity to androgen receptor pathway inhibitors (ARPIs) but are limited by lack of granular data. We hypothesize that SPOP mutations are associated with improved outcomes across the spectrum of advanced prostate cancer (PC). METHODS: Using the real-world clinicogenomic Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort database, we analyzed outcomes based on SPOP mutation status. The primary end point was overall survival (OS) from the diagnosis of metastatic disease. Secondary end points included real-world progression-free survival (PFS) and PSA90 response. RESULTS: Among 2,097 patients with metastatic PC, 5.5% (N = 115) had SPOP -mutated tumors. Compared with SPOP wild-type, patients with SPOP mutations were older at diagnosis (median 65 v 63 years; P = .001) and had higher (≥8) Gleason sum (68% v 54%; P = .02), higher incidence of lung metastasis (17% v 6%; P = .001), and increased frequency of intraductal features (13% v 5%; P < .001). SPOP mutations were associated with improved PSA90 response with first ARPI exposure in the castrate-resistant setting (60% v 40.6%; OR, 2.20 [95% CI, 1.15 to 4.19]; P = .02) but not in the castrate-sensitive setting (78.9% v 71.5%; OR, 1.49 [95% CI, 0.66 to 3.37]; P = .43). Median PFS with first ARPI did not differ in SPOP- mutated versus wild-type group in both the castrate-sensitive (24.2 v 19.2 months; hazard ratio [HR], 0.80 [95% CI, 0.49 to 1.32]; P = .39) and castrate-resistant settings (15.0 v 12.4 months; HR, 0.81 [95% CI, 0.58 to 1.12]; P = .20). In multivariable analysis, SPOP mutations were associated with improved OS (HR, 0.65, P = .02). CONCLUSION: SPOP mutations were associated with longer OS despite the presence of aggressive clinical features. The distinct clinical and molecular features of SPOP -mutated PC support its consideration as a unique molecular subtype with prognostic implications.


  • Early and Precise: Treating HRR Alterations in Hormone-Sensitive Prostate Cancer

    by Laura S. Graham, Evan Y. Yu

    Summary: Patients with prostate cancer and homologous recombination repair alterations face worse outcomes. Early use of PARP inhibitors, especially in BRCA-mutated cancers, is promising. However, optimal timing, sequencing, and benefits for non-BRCA alterations remain unclear, underscoring the need for well-designed clinical trials and personalized treatment discussions. See related article by Hage Chehade et al., p. 4101

  • Open Access

    Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study

    by H.R. Robinson, S. Lakritz, D.C. Pavlick, S.L. Davis, C.H. Lieu, C.J. Eule, L.S. Graham, P.E. Spiess, R. Li, A.M. Kamat, et al.


  • Open Access

    Cell Models of Castration Resistant and High Dose Testosterone-Resistant Prostate Cancer Recapitulate the Heterogeneity of Response Observed in Clinical Practice

    by Laura S. Graham, Lih-Jen Su, Andrew Nicklawsky, Frances Xiuyan Feng, David Orlicky, Joseph Petraccione, Maren Salzmann-Sullivan, Steven K. Nordeen, Thomas W. Flaig

    The use of supraphysiologic testosterone, particularly when alternated with an anti-androgen agent in men with metastatic castration-resistant prostate cancer (CRPC), has demonstrated promising results in clinical trials. As the use of this therapy in clinical practice is more widely adopted, there will be a growing need to understand the mechanisms of resistance. To that end, we independently derived three separate cell models of testosterone-sensitive CRPC. From each CRPC line, high dose testosterone-resistance (HTR) lines were selected. We demonstrated the differential response of the three CRPC lines to a high dose of testosterone in vitro and in vivo. We subsequently demonstrated the resistance of the HTR lines to testosterone and varying responses to testosterone withdrawal in vivo. The heterogeneity in responses to hormonal manipulation is correlated with varying levels of androgen receptor expression within the population. Overall, we show that we have developed three models of HTR that can be used to study the mechanisms of high dose testosterone resistance and identify potential therapeutic targets.

  • Open Access

    Clinical and Genomic Features of Androgen Indifferent Prostate Cancer

    by Jack Masur, Aakrosh Ratan, Krzysztof Wierbilowicz, Adanma Ayanambakkam, Michelle L. Churchman, Laura S. Graham, George Daniel Grass, Sumati Gupta, Sean Q. Kern, Jennifer King, et al.

    Androgen-indifferent prostate cancer (AIPC) is increasingly common and particularly lethal. Data describing these tumors are sparse, and AIPC remains a poorly understood malignancy. Utilizing the Oncology Research Information Exchange Network (ORIEN) database, we enriched for tumors with features of AIPC using previously described characteristics. Our AIPC cohort included three subgroups: aggressive variant prostate cancer (AVPC), neuroendocrine PC (NEPC), and double-negative PC (DNPC). Of 1496 total PC patients available for analysis, we identified 323 (22%) as MCRPC. Of those, 39 (12%) met AIPC criteria (17 AVPC, 13 NEPC, 9 DNPC) and 284 (88%) were non-AIPC. Forty-three percent of AIPC patients had de novo metastatic disease vs. 15% for non-AIPC (p = 0.003). Homologous recombination deficiency (HRD) and tumor mutational burden (TMB) did not differ between cohorts, but microsatellite instability scores (MSI) were significantly higher in AIPC (p = 0.019). Using Gene Set Enrichment Analysis (GSEA), we found that genes defining response to androgens and genes involved in oxidative phosphorylation were the most downregulated, whereas genes involved in epithelial–mesenchymal transition (EMT) and immune signaling were significantly upregulated in AIPC vs. non-AIPC. Our study demonstrates the potential for predefined criteria that aim to enrich for AIPC and suggests opportunities for therapeutic investigation.